Search for: "Ranbaxy Inc" Results 81 - 91 of 91
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Nov 2012, 6:50 pm by FDABlog HPM
District Court for the District of Columbia in which Mylan Laboratories Limited and Mylan Pharmaceuticals Inc. are challenging FDA’s decision that Ranbaxy Inc. is eligible for 180-day exclusivity for its generic versions of DIOVAN (valsartan) Tablets (see our previous post here) got us thinking about the instances in which FDA determined that 180-day exclusivity was not forfeited under FDC Act § 505(j)(5)(D)(i)(IV) because of some “extenuating circumstance.”  [read post]
18 Jan 2013, 2:06 pm by Bexis
  The Decherts are too involved in this litigation to comment publicly.There aren’t many research-oriented pharmaceutical companies based in Alabama, and after last week’s execrable decision in Wyeth, Inc. v. [read post]
1 Apr 2014, 9:50 pm by Zachary Ewing
Earlier in 2013, generic-drug-maker Ranbaxy agreed to pay $500 million in fines and settlement costs after the company pled guilty to federal drug safety violations. [read post]
25 Jan 2019, 12:08 pm by Katherine Kiziah
MDL No. 2879 – In Re: Marriott International, Inc., Customer Data Security Breach Litigation. [read post]
25 Jan 2019, 12:08 pm by Katherine Kiziah
MDL No. 2879 – In Re: Marriott International, Inc., Customer Data Security Breach Litigation. [read post]
16 Jun 2013, 9:36 pm by Jason Rantanen
In Australia the patentability of such materials has recently been confirmed by the Federal Court of Australia in Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65 (15 February 2013)[3], see Vaughn Barlow, CIPA, March 2013, 122-123. [read post]